Lilly Insulin Glargine Versus Lantus® in Type 2 Diabetes Mellitus Patients: India and East Asia Subpopulation Analyses of the ELEMENT 5 Study-Reference-Cited by-同舟云学术

Lilly Insulin Glargine Versus Lantus® in Type 2 Diabetes Mellitus Patients: India and East Asia Subpopulation Analyses of the ELEMENT 5 Study

Published:2019-05-22 Issue:8 Volume:39 Page:745-756
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Mohan Viswanathan,Ahn Kyu Jeung,Cho Young Min,Sahay Rakesh Kumar,Huang Chien-Ning,Kalra Sanjay,Chadha Manoj,Bhattacharya Indranil^ORCID,Kim So Yeon,Spaepen Erik

Funder

Eli Lilly and Company

Boehringer Ingelheim

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s40261-019-00798-1.pdf

Reference24 articles.

1. IDF Diabetes Atlas Eighth edition. 2017. Available from: http://diabetesatlas.org/resources/2017-atlas.html . Accessed July 2018.

2. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203.

3. Davies MJ, D’Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–701.

4. Owens DR. Insulin preparations with prolonged effect. Diabetes Technol Ther. 2011;13(Suppl 1):S5–14.

5. Hilgenfeld R, Seipke G, Berchtold H, Owens DR. The evolution of insulin glargine and its continuing contribution to diabetes care. Drugs. 2014;74(8):911–27.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus) in Chinese adults with type 2 diabetes: A phase III , randomized, open‐label, controlled trial;Diabetes, Obesity and Metabolism;2021-05-27